4//SEC Filing
Khan Najat 4
Accession 0002020969-25-000004
CIK 0001601830other
Filed
Nov 5, 7:00 PM ET
Accepted
Nov 6, 4:23 PM ET
Size
7.1 KB
Accession
0002020969-25-000004
Insider Transaction Report
Form 4
Khan Najat
DirectorChief R&D Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-11-05+169,851→ 169,851 totalExercise: $4.96Exp: 2035-11-05→ Class A Common Stock (169,851 underlying) - Award
Class A Common Stock
2025-11-05+84,925→ 753,122 total
Footnotes (2)
- [F1]This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on February 15, 2026, and every three months thereafter.
- [F2]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on December 5, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
Documents
Issuer
RECURSION PHARMACEUTICALS, INC.
CIK 0001601830
Entity typeother
Related Parties
1- filerCIK 0002020969
Filing Metadata
- Form type
- 4
- Filed
- Nov 5, 7:00 PM ET
- Accepted
- Nov 6, 4:23 PM ET
- Size
- 7.1 KB